<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04211389</url>
  </required_header>
  <id_info>
    <org_study_id>ARQ-151-302</org_study_id>
    <nct_id>NCT04211389</nct_id>
  </id_info>
  <brief_title>Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis</brief_title>
  <acronym>DERMIS-2</acronym>
  <official_title>A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects With Chronic Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcutis Biotherapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arcutis Biotherapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of ARQ-151 cream vs placebo applied once a day
      for 56 days by subjects with chronic plaque psoriasis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a parallel group, double blind, vehicle-controlled study in which ARQ-151 cream or
      vehicle is applied once daily x 8 weeks to subjects with psoriasis
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator Global Assessment Scale (IGA) Score Change</measure>
    <time_frame>Week 8</time_frame>
    <description>Achievement of an IGA score of 'clear' or 'almost clear' plus a 2-grade improvement from Baseline. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achievement of Psoriasis Area Severity Index 75 (PASI-75)</measure>
    <time_frame>Week 8</time_frame>
    <description>Psoriasis Area and Severity Index (PASI) is the most widely used tool for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intertriginous IGA (I-IGA) score of 'clear' or 'almost clear' PLUS a 2-grade improvement</measure>
    <time_frame>Week 8</time_frame>
    <description>For subjects with intertriginous area involvement, and with severity of the intertriginous lesions at least 'mild' (intertriginous IGA (I-IGA) ≥2) at Baseline, achievement of 'I-IGA' score of 'clear' or 'almost clear' PLUS a 2-grade improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Worst Itch (WI-NRS) pruritus score</measure>
    <time_frame>Week 2, Week 4, Week 8</time_frame>
    <description>In subjects with WI-NRS pruritus score ≥ 4 at baseline, achievement of a 4-point reduction in WI-NRS pruritus score. The WI-NRS is a 10 point scale with 0 as no itch and 10 as the worst itch imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Psoriasis Symptoms Diary (PSD) score</measure>
    <time_frame>Week 4, Week 8</time_frame>
    <description>The Psoriasis Symptoms Diary (PSD) evaluates subject psoriasis-related symptoms and experiences over the past 24-hours. Item scores range from 0 to 10, with higher scores indicating a worse condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achieving Psoriasis Area Severity Index-50 (PASI-50)</measure>
    <time_frame>Week 2, Week 4, Week 8</time_frame>
    <description>Psoriasis Area and Severity Index (PASI) is the most widely used tool for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of Psoriasis Area Severity Index-90 (PASI-90)</measure>
    <time_frame>Week 8</time_frame>
    <description>Psoriasis Area and Severity Index (PASI) is the most widely used tool for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Chronic Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>ARQ-151 cream 0.3%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARQ-151 cream vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARQ-151 0.3% cream</intervention_name>
    <description>ARQ-151 0.3% cream</description>
    <arm_group_label>ARQ-151 cream 0.3%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARQ-151 vehicle cream</intervention_name>
    <description>ARQ-151 vehicle cream</description>
    <arm_group_label>ARQ-151 cream vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants legally competent to sign and give informed consented and if appropriate
             assent as required by local laws

          -  Males and females ages 2 years and older (inclusive)

          -  Clinical diagnosis of psoriasis vulgaris of at least 6 months duration (3 months for
             children) as determined by the Investigator

          -  Females of childbearing potential (FOCBP) must have a negative pregnancy test at
             Screening (Visit 1) and Baseline (Visit 2). In addition, sexually active FOCBP must
             agree to use at least one form of highly effective contraception throughout the trial.

          -  In good health as judged by the Investigator, based on medical history, physical
             examination, serum chemistry labs, hematology values, and urinalysis.

          -  Subjects considered reliable and capable of adhering to the Protocol and visit
             schedule, according to the judgment of the Investigator.

        Exclusion Criteria:

          -  Planned excessive exposure of treated area(s) to either natural or artificial
             sunlight, tanning bed or other LED.

               -  Females who are pregnant, wishing to become pregnant during the study, or are
                  breast-feeding.

               -  Previous treatment with ARQ-151 or its active ingredient

               -  Subjects with any serious medical condition or laboratory abnormality that would
                  prevent study participation or place the subject at significant risk, as
                  determined by the Investigator.

               -  Subjects with a history of chronic alcohol or drug abuse within 6 months of
                  initiation of investigational product

               -  Subjects who are unable to communicate, read or understand the local language, or
                  who display another condition, which in the Investigator's opinion, makes them
                  unsuitable for clinical study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Berk, MD</last_name>
    <role>Study Director</role>
    <affiliation>Arcutis Biotherapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Berk, MD</last_name>
    <phone>805-418-5006</phone>
    <phone_ext>5</phone_ext>
    <email>studyinquiry@arcutis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 203</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 239</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 225</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 220</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 208</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 215</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 223</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 237</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 228</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33770</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 201</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 209</name>
      <address>
        <city>Sweetwater</city>
        <state>Florida</state>
        <zip>33172</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 214</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 217</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 211</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 213</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 224</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 212</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 216</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 227</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 219</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 231</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 240</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 236</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>03801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 222</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 229</name>
      <address>
        <city>Broomall</city>
        <state>Pennsylvania</state>
        <zip>19008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 233</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37922</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 221</name>
      <address>
        <city>Murfreesboro</city>
        <state>Tennessee</state>
        <zip>37130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 206</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 238</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 210</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 230</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 207</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 226</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V0C6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 232</name>
      <address>
        <city>Winnepeg</city>
        <state>Manitoba</state>
        <zip>R3M 3Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 234</name>
      <address>
        <city>Fredericton</city>
        <state>New Brunswick</state>
        <zip>E3B 1G9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 205</name>
      <address>
        <city>Ajax</city>
        <state>Ontario</state>
        <zip>L1S 7K8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 218</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 235</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4W 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 204</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 1E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arcutis Study Inquiry</last_name>
      <phone>805-418-5006</phone>
      <phone_ext>5</phone_ext>
      <email>studyinquiry@arcutis.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 23, 2019</study_first_submitted>
  <study_first_submitted_qc>December 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2019</study_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

